isoxazoles has been researched along with Di Guglielmo Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beneytout, JL; Leger, DY; Liagre, B | 1 |
| Bakker Schut, TC; de Grooth, BG; Florians, A; Greve, J; Radosević, K | 1 |
2 other study(ies) available for isoxazoles and Di Guglielmo Disease
| Article | Year |
|---|---|
Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Humans; Isoxazoles; K562 Cells; Leflunomide; Leukemia, Erythroblastic, Acute; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; NF-kappa B; Organophosphorus Compounds; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine | 2006 |
Signal processing in slit-scan flow cytometry of cell conjugates.
Topics: Barbiturates; Cell Adhesion; Cytotoxicity, Immunologic; Electronics; Flow Cytometry; Fluorescence; Humans; Isoxazoles; Killer Cells, Natural; Leukemia, Erythroblastic, Acute; Membrane Potentials; Scattering, Radiation; Tumor Cells, Cultured | 1993 |